1. A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. (12th June 2013) Authors: Outteryck, O.; Ongagna, J.C.; Brochet, B.; Rumbach, L.; Lebrun‐Frenay, C.; Debouverie, M.; Zéphir, H.; Ouallet, J.C.; Berger, E.; Cohen, M.; Pittion, S.; Laplaud, D.; Wiertlewski, S.; Cabre, P.; Pelletier, J.; Rico, A.; Defer, G.; Derache, N.; Camu, W.; Thouvenot, E. Journal: European journal of neurology Issue: Volume 21:Number 1(2014:Jan.) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗